252 related articles for article (PubMed ID: 36860165)
21. Epigenetic therapy in hematological cancers.
Dimopoulos K; Grønbaek K
APMIS; 2019 May; 127(5):316-328. PubMed ID: 30859683
[TBL] [Abstract][Full Text] [Related]
22. Current Status of Epigenetics and Anticancer Drug Discovery.
Jin P; Chen X
Anticancer Agents Med Chem; 2016; 16(6):699-712. PubMed ID: 26567620
[TBL] [Abstract][Full Text] [Related]
23. Epigenetic modifications as therapeutic targets.
Kelly TK; De Carvalho DD; Jones PA
Nat Biotechnol; 2010 Oct; 28(10):1069-78. PubMed ID: 20944599
[TBL] [Abstract][Full Text] [Related]
24. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
25. The impact of histone deacetylase inhibitors on immune cells and implications for cancer therapy.
Moran B; Davern M; Reynolds JV; Donlon NE; Lysaght J
Cancer Lett; 2023 Apr; 559():216121. PubMed ID: 36893893
[TBL] [Abstract][Full Text] [Related]
26. Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future.
Lamb MG; Rangarajan HG; Tullius BP; Lee DA
Stem Cell Res Ther; 2021 Mar; 12(1):211. PubMed ID: 33766099
[TBL] [Abstract][Full Text] [Related]
27. Inhibitors of DNA Methylation and Histone Deacetylation as Epigenetically Active Drugs for Anticancer Therapy.
Myasoedova VA; Sukhorukov V; Grechko AV; Zhang D; Romanenko E; Orekhov V; Orekhov AN
Curr Pharm Des; 2019; 25(6):635-641. PubMed ID: 30950345
[TBL] [Abstract][Full Text] [Related]
28. DNA demethylating agents and histone deacetylase inhibitors in hematologic malignancies.
Fandy TE; Carraway H; Gore SD
Cancer J; 2007; 13(1):40-8. PubMed ID: 17464245
[TBL] [Abstract][Full Text] [Related]
29. Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer.
Falahi F; van Kruchten M; Martinet N; Hospers GA; Rots MG
Breast Cancer Res; 2014 Jul; 16(4):412. PubMed ID: 25410383
[TBL] [Abstract][Full Text] [Related]
30. miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies.
Amodio N; Rossi M; Raimondi L; Pitari MR; Botta C; Tagliaferri P; Tassone P
Oncotarget; 2015 May; 6(15):12837-61. PubMed ID: 25968566
[TBL] [Abstract][Full Text] [Related]
31. New directions in treating peripheral T-cell lymphomas (PTCL): leveraging epigenetic modifiers alone and in combination.
Ma H; O'Connor OA; Marchi E
Expert Rev Hematol; 2019 Mar; 12(3):137-146. PubMed ID: 30782038
[TBL] [Abstract][Full Text] [Related]
32. Targeting epigenetic abnormalities with histone deacetylase inhibitors.
Conley BA; Wright JJ; Kummar S
Cancer; 2006 Aug; 107(4):832-40. PubMed ID: 16826577
[TBL] [Abstract][Full Text] [Related]
33. The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease.
Cosenza M; Pozzi S
Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30096875
[TBL] [Abstract][Full Text] [Related]
34. DNA demethylating agents and epigenetic therapy of cancer.
Mani S; Herceg Z
Adv Genet; 2010; 70():327-40. PubMed ID: 20920754
[TBL] [Abstract][Full Text] [Related]
35. Histone Deacetylase and Enhancer of Zeste Homologue 2 Dual Inhibitors Presenting a Synergistic Effect for the Treatment of Hematological Malignancies.
Lu D; Wang C; Qu L; Yin F; Li S; Luo H; Zhang Y; Liu X; Chen X; Luo Z; Cui N; Kong L; Wang X
J Med Chem; 2022 Oct; 65(19):12838-12859. PubMed ID: 36153841
[TBL] [Abstract][Full Text] [Related]
36. Entinostat for treatment of solid tumors and hematologic malignancies.
Knipstein J; Gore L
Expert Opin Investig Drugs; 2011 Oct; 20(10):1455-67. PubMed ID: 21888556
[TBL] [Abstract][Full Text] [Related]
37. Epigenetic Treatment Options in Urothelial Carcinoma.
Pinkerneil M; Hoffmann MJ; Niegisch G
Methods Mol Biol; 2018; 1655():289-317. PubMed ID: 28889393
[TBL] [Abstract][Full Text] [Related]
38. Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions.
Kopp LM; Ray A; Denman CJ; Senyukov VS; Somanchi SS; Zhu S; Lee DA
Mol Immunol; 2013 Jul; 54(3-4):296-301. PubMed ID: 23328088
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors.
Miller CP; Singh MM; Rivera-Del Valle N; Manton CA; Chandra J
J Biomed Biotechnol; 2011; 2011():514261. PubMed ID: 21765634
[TBL] [Abstract][Full Text] [Related]
40. Epigenetic modulation of neuroblastoma enhances T cell and NK cell immunogenicity by inducing a tumor-cell lineage switch.
Cornel AM; Dunnebach E; Hofman DA; Das S; Sengupta S; van den Ham F; Wienke J; Strijker JGM; van den Beemt DAMH; Essing AHW; Koopmans B; Engels SAG; Lo Presti V; Szanto CS; George RE; Molenaar JJ; van Heesch S; Dierselhuis MP; Nierkens S
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36521927
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
